Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance

@article{Elliott1995DextromethorphanSE,
  title={Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance},
  author={Kathryn J. Elliott and Marina Brodsky and Alexandra Hynansky and Kathleen M. Foley and Charles E Inturrisi},
  journal={Neurology},
  year={1995},
  volume={45},
  pages={S66 - S68}
}
The oral antitussive dextromethorphan is a clinically available N-methyl-D-aspartate receptor antagonist. Dextromethorphan has analgesic efficacy in the experimental formalin test, blocks the nociceptive activation of the immediate-early gene, c-fos proto-oncogene, and prevents and reverses the development of opiate analgesic tolerance in experimental models. These data suggest that dextromethorphan should be evaluated in a controlled clinical trial for analgesic efficacy in zoster-associated… 
Antinociceptive and nociceptive actions of opioids.
TLDR
The neuroplastic changes elicited by opioid exposure reflect adaptive changes to promote increased pain transmission and consequent diminished antinociception (i.e., tolerance).
Cold Pain Threshold and Role of NMDA Receptor Antagonists
TLDR
Cold pain threshold was higher in men and individuals over than 30-year-old and decreased significantly after administration of clonidine and dextromethorphan conjointly and Acta Med Iran 2018;56(11):720-725.
N‐Methyl‐d‐aspartate receptor modulators block hyperalgesia induced by acute low‐dose morphine
TLDR
The tail‐flick test was used to assess the effects of morphine alone and in combination with the NMDA receptor modulators on the development of morphine‐induced hyperalgesia in mice.
Dextromethorphan potentiates the antinociceptive effects of morphine and the delta-opioid agonist SNC80 in squirrel monkeys.
TLDR
The antinociceptive effects of DXM administered alone or in combination with morphine or the delta-opioid receptor (DOR) agonist SNC80 were potentiated by DXM and these combinations did not significantly alter RR.
Search for the “ideal analgesic” in pain treatment by engineering the mu‐opioid receptor
TLDR
This article decides to explore the possibility of using virus to deliver the mutant mu‐opioid receptor at the various sites of the nociceptive pathway and induce the antinocICEptive responses with the systemic administration of opioid antagonists.
Mu Opioids and Their Receptors: Evolution of a Concept
TLDR
Understanding of these morphine-like agents and their receptors has undergone an evolution in thinking over the past 35 years, which now reveals a complexity of the morphine- like agents andtheir receptors that had not been previously appreciated.
Opioids in the Treatment of Headache: Perspective from the Bench
TLDR
Evidence is emerging that medication-induced enhanced pain is not unique to opioids, but may be generalized to other analgesic classes acting through G-protein coupled receptor systems, which would lead to improved therapeutic management of long-term painful conditions, including recurrent headache.
...
1
2
3
...

References

SHOWING 1-10 OF 34 REFERENCES
Dextromethorphan inhibits NMDA-induced convulsions.
Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801.
TLDR
The present studies suggest that NMDA receptors may be important in the development of opiate tolerance and dependence.
Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614.
TLDR
The demonstration that LY274614 can prevent and reverse the development of morphine tolerance without reducing the analgesic response suggests that the adaptive system involved in the development and maintenance of tolerance requires a functional N-methyl-D-aspartate receptor.
...
1
2
3
4
...